GitLab Stock Is Down 70% From 2021 Highs but One Fund Is Betting $10 Million on Its Performance

Massachusetts-based TFJ Management disclosed a third-quarter purchase of 116,490 GitLab (GTLB) shares, raising its position to 221,259 shares with a quarter-end market value of $9.97 million and representing 6.72% of its reported 13F AUM; the incremental buy increased the stake by an estimated $5.25 million. GitLab trades at $38.00 (down ~32% over the past year) with a $6.4 billion market cap; recent operating results show revenue of $244.4 million in the latest quarter (up 25% year-over-year), TTM revenue of $906.25 million, adjusted free cash flow of $27.2 million, a non-GAAP operating margin of 18%, dollar-based net retention of 119%, and 23% growth in >$100k customers. The filing signals institutional conviction in a volatile enterprise-software name where fundamentals are improving despite a large drawdown from post-IPO highs, implying opportunity for patient, growth-oriented investors without concentrated exposure.

Analysis

Market structure: TFJ’s third‑quarter accumulation of 116k GTLB shares signals selective institutional appetite for volatile, high‑growth DevOps exposure; direct beneficiaries are GitLab (GTLB) and its enterprise customers, while legacy point solutions (internal CI/CD tooling, smaller niche vendors) face pressure. With TTM revenue ~$906m and market cap $6.4bn, the stock trades as a growth multiple (~7x revenue) despite ~25% top‑line growth—pricing reflects demand for re‑risked growth rather than immediate cash flow conversion.

Risk assessment: Tail risks include a sharp enterprise IT spend pullback ( >10% y/y contraction in cyclical budgets), a security breach undermining trust, or aggressive open‑source competition that could drop dollar retention below 110%; any of these could erase >40% of market cap. Immediate impact (days) will be headline‑sensitive, short term (0–6 months) hinges on guidance/DBNR cadence, long term (12–36 months) depends on sustaining >20% ARR growth and margin expansion to 15–20% adjusted operating margin.

Trade implications: Direct play—establish a tactical 2–3% portfolio long in GTLB on entries <=$38, add on pullback to <$25; target 12–24 month upside 50–100% if growth/margins continue. Option strategies—buy Jan 2027 LEAP calls (1x $40 strike) for asymmetric upside or a 6‑month call spread (buy Mar 2026 $35, sell Mar 2026 $55) to cap cost; sell 90‑day cash‑secured $30 puts to acquire on weakness.

Contrarian angles: The market is discounting stable enterprise economics (119% DBNR, +23% $100k+ customers) while over‑penalizing headline volatility—this is a classic growth‑reset mispricing if macro stabilizes. Watch for re‑rating catalysts (sequential acceleration in large deals, sustained free cash flow) and beware momentum squeezes if concentration in funds like TFJ triggers stop‑runs.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in GitLab (GTLB) at market price <= $38; set an initial 20% trailing stop and plan to hold 12–24 months with upside target 50–100% if revenue growth remains >=20% and adjusted operating margin approaches 15–20%.
• Execute a relative‑value pair: long GTLB (notional X) and short Atlassian (TEAM) at 0.6x notional (short smaller) for 12 months to express share‑gain thesis in DevOps; rebalance if GTLB/TEAM price ratio moves >20% from entry.
• Use options for asymmetric exposure: buy Jan 2027 LEAP calls (approx. $40 strike) sized to equal 1–1.5% portfolio risk, or deploy a lower‑cost Mar 2026 call spread (buy $35 / sell $55) to limit premium; alternatively sell a 90‑day cash‑secured put at $30 to collect premium and set max assignment price.
• Reduce cyclical defensive overweights by 1–2% to fund GTLB exposure; reallocate into enterprise SaaS names with DBNR >110% and positive FCF (e.g., GTLB, DDOG) and trim outperformance tech if macro PMI slips below 50 for two consecutive months.